Literature DB >> 8234706

Refractory ascites: early experience in treatment with transjugular intrahepatic portosystemic shunt.

H Ferral1, H Bjarnason, S A Wegryn, G J Rengel, G K Nazarian, J M Rank, S M Tadavarthy, D W Hunter, W R Castaneda-Zuniga.   

Abstract

PURPOSE: To evaluate the transjugular intrahepatic portosystemic shunt (TIPS) in treatment of refractory ascites.
MATERIALS AND METHODS: Fourteen patients with chronic liver disease and portal hypertension were included in a prospective study. Six patients had Child-Pugh class B disease; eight had class C disease. Indications for TIPS were three previous hospital admissions over 9 months for treatment of tense ascites, no response to diuretic therapy, or an occluded peritoneovenous shunt with tense ascites. The volume of ascitic fluid was sonographically evaluated before and after TIPS placement.
RESULTS: The technical success rate for TIPS creation was 93%. Mean portosystemic gradient decreased from 22.8 mm Hg +/- 7.2 before TIPS placement to 11.3 mm Hg +/- 3.6 after TIPS (P = .005). Complete resolution of ascites was achieved in seven (50%) patients. Treatment failed in seven; five had Child-Pugh class C disease, and four of these had a Child-Pugh score greater than 11.
CONCLUSION: These results are comparable to those for other forms of treatment of ascites. The authors do not, however, recommend TIPS in patients with a Child-Pugh score greater than 11.

Entities:  

Mesh:

Year:  1993        PMID: 8234706     DOI: 10.1148/radiology.189.3.8234706

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

Authors:  G Nasr; A Hassan; S Ahmed; A Serwah
Journal:  J Cardiovasc Dis Res       Date:  2010-07

2.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome.

Authors:  M D Uhl; D B Roth; C A Riely
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

4.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

5.  Bacteremia and "Endotipsitis" following transjugular intrahepatic portosystemic shunting.

Authors:  Meir Mizrahi; Lilach Roemi; Daniel Shouval; Tomer Adar; Maya Korem; Alon Moses; Alan Bloom; Oren Shibolet
Journal:  World J Hepatol       Date:  2011-05-27

6.  Wallstent misplacement into the paraumbilical vein during TIPS from the left hepatic vein: correction by placing a second stent through the mesh of the first stent.

Authors:  M P Ghysels; O Le Moine; J Devière; P Cuvelliez; F Rypens; M Adler; J L Struyven
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Jan-Feb       Impact factor: 2.740

7.  Transjugular intrahepatic portosystemic shunt after previous recanalization of a chronically thrombosed portal vein via a transmesenteric approach.

Authors:  O Matsui; J Yoshikawa; M Kadoya; T Gabata; T Takashima; T Urabe; M Unoura; K Kobayashi
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Sep-Oct       Impact factor: 2.740

Review 8.  The use and misuse of transjugular intrahepatic portasystemic shunts.

Authors:  A J Sanyal
Journal:  Curr Gastroenterol Rep       Date:  2000-02

9.  Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion.

Authors:  P M Pattynama; B van Hoek; L J Kool
Journal:  Cardiovasc Intervent Radiol       Date:  1995 May-Jun       Impact factor: 2.740

10.  TIPS for management of refractory ascites: response and survival are both unpredictable.

Authors:  Paul J Thuluvath; Jasdeep S Bal; Sally Mitchell; Gunnar Lund; Anthony Venbrux
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.